Pilot Projects and Trans-Network Activities Core

项目概要/摘要：试点项目和跨网络活动核心 试点项目和跨网络活动核心的目标是支持研究的发展 使用PDX模型的项目将推进PDTC和PDXNet的使命。核心将有助于培养 使用概括人类疾病的充分表征的PDX模型进行协作、转化研究。 项目将扩大转化研究的范围，增加致力于研究的研究人员的数量。 使用PDX模型测试CTEP药物，以开发I/II期临床试验所需的临床前依据 审判申请（RFA）的申请要求，每年将有两个50 000美元的奖项。分之一内 PDTC和一个对非PDXNet成员开放。这些项目的目标是支持 PDTC的翻译目标是通过使用PDX模型或研究来推进翻译研究 增强PDTC实验验证和重现性的方法。申请要求 (RFA)将每年申请一次基于PDX的项目。所有发展研究项目的申请， 由科学家组成的试点研究计划咨询委员会（代表基础和 应用科学），具有实体瘤癌症方面的专业知识，生物统计学家，患者倡导者和特设 委员会成员，必要时（特殊专长，无利益冲突）。该委员会将提出建议 PDTC领导委员会将做出最终的资金决定。 相关性 所提出的工作将导致PDX作为人类疾病模型的利用率增加， 基于生物标志物在患者亚群中检测CTEP药物的临床前依据。

Project Summary/Abstract: Pilot Projects and Trans-Network Activities Core The goal of the Pilot Projects and Trans-Network Activities Core is to support the development of research projects using PDX models that will advance the mission of the PDTC and PDXNet. The core will help to foster collaborative, translational research using well-characterized PDX models that recapitulate human disease. Projects will expand the scope of translational research and increase the number of investigators committed to testing CTEP agents using PDX models for developing the preclinical justification needed for Phase I/II clinical trials. Requests for Application (RFA) for two awards of $50,000 dollars a year will be solicited. One within the PDTC and one that is open to non-PDXNet members. The goal of these projects will be to support the translational goals of the PDTC to advance translational research through the use of PDX models or, research methods to enhance experimental validation and reproducibility across PDTCs. Requests for Applications (RFA) for PDX based projects will be requested annually. All developmental research project applications will be reviewed by Pilot Research Program Advisory Committee consisting of scientists (representing basic and applied science) with expertise in solid tumor cancers, a biostatistician, a patient advocate, and ad hoc members, as necessary (special expertise, no conflict of interest). This committee will make recommendations to the PDTC Leadership Committee, which will make final funding decisions. Relevance The work proposed will lead to increased utilization of PDXs as models of human disease that can be used as the preclinical justification for testing CTEP agents in patient sub-populations based on biomarkers.